The phase Ⅱ clinical trial of Seratia Marcescens Anticancer Vaccine (S311)for malignant pleural effusions
ZHU Yunzhong , SHI Heling, QIAN Hao, HUANG Wenxia, HONG Zhuan, ZHANG Yiping, XU Nong, ZHANG Li, LIU Donggeng, DONG Zhongsheng, LI Shufen, ZHANG Lijian, ZHENG Wen. Beijing Thoracic Tumor Research Institute, Beijing 101149, P.R.China
Objective To evaluate the effect and adverse reactions of Seratia Marcescens Anticancer Vaccine (S311) in the treatment of malignant pleural effusions. Methods 0.32?mg of S311 was administered into intracavity once a week, for successive three weeks, after draining off the pleural cavity completely by thoracocentesis or chest drainage. Results Two hundred and forty-one patients with malignant effusions finished the arrangement of S311 therapy. The overall response rate was 92.1%. The main adverse reactions were fever and pleuritic pain. Some patients had chill, dyspnea, nausea and vomiting. Liver dysfunction was observed in a few cases. Conclusion S311 is an effective drug for malignant pleural effusions.
【CateGory Index】： R730.5